Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD13-02 in Relapsed/Refractory CD7+ Hematological Malignancies
NCT05895994Phase 1Completed
- Sponsor
- MEI HENG
- Start
- Mar 2023
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD13-02 in acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL) and acute myeloid leukemia (AML), sponsored by MEI HENG. Primary endpoint: Overall Response Rate at 12 weeks. Started Mar 2023; status: completed.
02
Drugs
RD13-02
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05895994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05895994.